Wed 23rd Apr 14, 07:4
Following yesterday's surge on the back of bid speculation and M&A activity within the pharma sector, today's session looks set for a fairly flat start, with the top tier expected to inch marginally lower early on.
Search news for stories that mention a company:
Show only the stories that interest you with news filter.
Footfall, sales at UK shopping centres improve; Leases signed above ERV; Occupancy remains high. 41 minutes ago
Oil services and engineering group Amec is trading in line with hopes, although it cautioned about the potential impact of the strong pound against the US and Canadian dollar. 46 minutes ago
The dollar and the euro traded in narrow ranges while the Australian dollar skidded ahead of first quarter Australian consumer price data, which should give clues on the prospects of an interest rate hike this year. 49 minutes ago
Crude oil futures came under pressure in volatile trading on Tuesday amid concern about rising stockpiles and as the current front month contract expired. 49 minutes ago
Power systems giant Rolls-Royce has won a contract to service AE 1107C engines for V-22 aircraft operated by the US Marine Corps and Air Force. 51 minutes ago
The EUR/USD has seen little action for almost a week, as the cross has been trapped in a tight range of around 90 pips. The cross is trading close to the 1.3820 level on Wednesday morning, ahead of the release of several preliminary PMI releases in the euro area. 1 hour ago
Disclaimer: This news feed is provided by Digital Look Ltd. BullBearings Ltd do not necessarily share the views expressed within the stories. The stories are for general information purposes only and not a solicitation or personal reccomendation to deal. BullBearings Ltd accepts no liability or responsibility for any of the content contained in the information provided by Digital Look Ltd.
In this, the first of a series of four articles, I will explain some forex misconceptions are, and outline the feature that is the real “holy grail” of the market. In the following three parts, I will show how a robust trading strategy can be built that will give the new or aspiring trading an edge with an overwhelming probability of profitability over the long run.
In order to begin our journey, it helps to begin with an allegorical story, in order to demonstrate the nature and challenge of the struggle of trading.
Those who have followed me for some years will know I am a fan of seasonality and as I have explained in previous updates, financial markets do not go up or down evenly throughout the year in a nice orderly straight line; that would be far too easy.
If we invested $10,000 in the Dow Jones on 1st November and and then taken our money out on April 30st from 1950 to date we would now have over $950,000. We would have been out of the market May until end of October each year missing a few crashes in the process.
The USD/CHF pair fell during the session on Friday, but did so in a relatively tame manner, leading me to believe there are still opportunities for short-selling.
After all, we have seen for strong selloffs as far as daily candles are concerned, and then have finally see the market settle down for the Friday session.
Cloud computing services provider Nasstar (NASA) has been transformed by its acquisition of rival e-know.net. The integration of the operations is already far advanced and the business should be profitable this year.
e-know.net was established by David Redwood in 2000 and it was much larger than Nasstar, which paid £13m in cash and shares for the company in January and raised £10.5m from a placing at 5p a share.
Shares in Abcam (ABC), the provider of antibodies for the life sciences research and testing sector, have fallen by more than a quarter in recent weeks after a profit warning at the beginning of last month, with some investors clearly now having doubts about the long term future for the company. But new research might indicate things aren't as bad as some doomsayers believe.
Independent antibody search engine CiteAb has released new data today that suggests that this is a temporary dip for Abcam, with a brighter future ahead.